Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Contineum Therapeutics (CTNM) Accumulated Depreciation & Amortization (2023 - 2024)

Contineum Therapeutics has reported Accumulated Depreciation & Amortization over the past 2 years, most recently at $258000.0 for Q4 2024.

  • Quarterly results put Accumulated Depreciation & Amortization at $258000.0 for Q4 2024, down 82.53% from a year ago — trailing twelve months through Dec 2024 was $258000.0 (down 82.53% YoY), and the annual figure for FY2024 was $258000.0, down 82.53%.
  • Accumulated Depreciation & Amortization for Q4 2024 was $258000.0 at Contineum Therapeutics, down from $1.5 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for CTNM hit a ceiling of $1.5 million in Q4 2023 and a floor of $258000.0 in Q4 2024.